Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon

Core Insights - Genmab (GMAB) reported strong Q4 2024 results, with revenue guidance for 2025 slightly ahead of Street consensus and expense guidance below expectations [2] Financial Performance - Q4 2024 results were strong, contributing to a rebound in the stock price following the earnings report [2] Future Outlook - The 2025 revenue guidance provided by Genmab is slightly above market expectations, indicating positive growth prospects [2]